Statin-induced necrotizing myositis - A discrete autoimmune entity within the "statin-induced myopathy spectrum"

Autoimmunity Reviews

Volumn 12, Issue 12, 2013, Pages 1177-1181

  Hamann, Philip D H ^a   Cooper, Robert G ^b   McHugh, Neil J ^a   Chinoy, Hector ^b  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

200 100kDa; Antibody; HMGCR; Myositis; Necrotizing; Statin

Indexed keywords

3 HYDROXY 3METHYLGLUTARYL COENZYME A REDUCTASE; AMIODARONE; AUTOANTIBODY; COLCHICINE; CREATINE KINASE; CYCLOSPORIN A; FIBRIC ACID DERIVATIVE; HLA DQA1 ANTIGEN; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; UNCLASSIFIED DRUG; WARFARIN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG EXPOSURE; DRUG INDUCED DISEASE; DYSFERLINOPATHY; ELECTROMYOGRAPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; LIFESTYLE MODIFICATION; MUSCLE BIOPSY; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PATHOGENESIS; PHYSIOTHERAPY; REVIEW; RISK FACTOR; SMOKING CESSATION; STATIN INDUCED NECROTIZING MYOSITIS; WEIGHT REDUCTION;

200/100KDA; ANTIBODY; HMGCR; MYOSITIS; NECROTIZING; STATIN;

AUTOANTIBODIES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOSITIS;

EID: 84884700747     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.07.001     Document Type: Review

References (33)

1. Simons J. The $10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the [Internet]. money.cnn.com [cited 2013 Mar 3]. Available from:. http://money.cnn.com/magazines/fortune/fortune_archive/2003/01/20/335643/.
2. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum Sep 2010, 62(9):2757-2766.
3. Pasternak R.C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation Aug 20 2002, 106(8):1024-1028. [Internet, Available from: http://journals.lww.com/epidem/Abstract/2001/09000/Lipid_Lowering_Drugs_and_Risk_of_Myopathy__A.17.aspx].
4. Armitage J. The safety of statins in clinical practice. Lancet Nov 30 2007, 370(9601):1781-1790.
5. de Sauvage Nolting P.R.W., Buirma R.J.A., Hutten B.A., Kastelein J.J.P., Dutch ExPRESS Investigator Group Two-year efficacy and safety of simvastatin 80mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol Jul 15 2002, 90(2):181-184.
6. Franc S., Dejager S., Bruckert E., Chauvenet M., Giral P., Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther Sep 2003, 17(5-6):459-465.
7. Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation Dec 19 2006, 114(25):2788-2797.
8. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins12. J Am Coll Cardiol Am Coll Cardiol Found 2002, 40(3):567-572.
9. Reeves W.H., Nigam S.K., Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A Dec 1986, 83(24):9507-9511.
10. Targoff I.N., Johnson A.E., Miller F.W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum Sep 1990, 33(9):1361-1370.
11. Levin M.I., Mozaffar T., Al-Lozi M.T., Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology Mar 1998, 50(3):764-767.
12. MD AMR, MD FCE Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc Jan 2013, 88(1):83-105.
13. Liang C., Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol Nov 2011, 23(6):612-619.
14. Smith B. Skeletal muscle necrosis associated with carcinoma. J Pathol 1969, 97(2):207-210. [Wiley Online Library].
15. Wegener S., Bremer J., Komminoth P., Jung H.H., Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol 2010, 3(1):88-92.
16. Miller T., Al-Lozi M.T., Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry Aug 21 2002, 73(4):420-428.
17. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med Feb 13 1975, 292(7):344-347.
18. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med Feb 20 1975, 292(8):403-407.
19. Fernandez G., Spatz E.S., Jablecki C., Phillips P.S. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med Jun 2011, 78(6):393-403.
20. Bernatsky S., Joseph L., Pineau C.A., Belisle P., Boivin J.F., Banerjee D., et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis Jun 12 2009, 68(7):1192-1196.
21. Mammen A.L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum Feb 25 2011, 63(3):713-721.
22. Mammen A.L., Pak K., Williams E.K., Brisson D., Coresh J., Selvin E., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res Jan 25 2012, 64(2):269-272.
23. Gunawardena H., Betteridge Z.E., McHugh N.J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology Jun 2009, 48(6):607-612.
24. Dalakas M.C. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry Aug 2009, 80(8):832-838.
25. Casciola-Rosen L., Mammen A.L. Myositis autoantibodies. Curr Opin Rheumatol Nov 2012, 24(6):602-608.
26. Mammen A.L., Gaudet D., Brisson D., Christopher-Stine L., Lloyd T.E., Leffell M.S., et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res Aug 2012, 64(8):1233-1237.
27. Werner J.L., Christopher-Stine L., Ghazarian S.R., Pak K.S., Kus J.E., Daya N.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum Nov 28 2012, 64(12):4087-4093.
28. Stenzel W., Goebel H.H., Aronica E. Review: immune-mediated necrotizing myopathies-a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol Dec 2012, 38(7):632-646.
29. Padala S., Thompson P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis May 1 2012, 222(1):15-21. [Elsevier Ireland Ltd.].
30. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F.L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord Feb 2007, 17(2):194-200.
31. Benveniste O., Romero N.B. Myositis or dystrophy? Traps and pitfalls. La Presse Méd Apr 2011, 40(4 Pt 2):e249-e255.
32. Link E., Parish S., Armitage J., Bowman L., Heath S., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med Aug 21 2008, 359(8):789-799. SEARCH Collaborative Group.
33. Grable-Esposito P., Katzberg H.D., Greenberg S.A., Srinivasan J., Katz J., Amato A.A. Muscle Nerve 2010, 41(2):185-190.